State of Wyoming’s Celldex Therapeutics CLDX Stock Holding History

State of Wyoming’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.5K	Buy	+658	New	+$21.3K	﹤0.01%	1775
2022 Q3	–	Sell	-214	Closed	-$6K	–	1590
2022 Q2	$6K	Sell	214 -623	-74%	-$18.1K	﹤0.01%	1701
2022 Q1	$29K	Sell	837 -271	-24%	-$8.66K	0.01%	1325
2021 Q4	$42K	Buy	1,108 +519	+88%	+$22.6K	0.02%	1189
2021 Q3	$32K	Sell	589 -448	-43%	-$21K	0.02%	868
2021 Q2	$36K	Buy	1,037 +709	+216%	+$19.5K	0.02%	823
2021 Q1	$7K	Buy	+328	New	+$7.53K	0.01%	417

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State of Wyoming's CLDX Position: Q2 2026 in Review

State of Wyoming opened a new position in Celldex Therapeutics (CLDX) in Q2 2026: 658 shares worth $24.5K. The stake represents ﹤0.01% of the portfolio and ranks #1775 among its holdings. This is a return to the name: State of Wyoming previously reported a position in CLDX as recently as Q2 2022.

State of Wyoming first reported a position in CLDX in Q1 2021 and has held it in 7 quarters since. The position peaked at $42K in Q4 2021. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

State of Wyoming held 658 shares of Celldex Therapeutics worth $24.5K as of Q2 2026.
Celldex Therapeutics was a new State of Wyoming position in Q2 2026.
Celldex Therapeutics made up ﹤0.01% of State of Wyoming's portfolio in Q2 2026, its #1775 holding.
State of Wyoming first reported a position in Celldex Therapeutics in Q1 2021 and has held it in 7 quarters since.
State of Wyoming's Celldex Therapeutics position peaked at $42K in Q4 2021.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on State of Wyoming's 13F filing for Q2 2026, filed 6 Aug 2026.